—

Kyowa Kirin Co., Ltd.

Phase 2 Estimated

KK2430

Hematologic Neoplasms

Countdown

297days

Phase 2 readout · ~ Apr 30, 2027 estimated

What's at stake Phase 2 trial results for KK2430 in Hematologic Neoplasms are due ~ Apr 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · ClinicalTrials.gov verified 15h ago

“CT.gov NCT07629726: Phase 2 trial, sponsor Kyowa Kirin Co., Ltd., drug KK2430. Primary completion date 2027-04 (estimated).”

Add to calendar Post on X Reddit

Provenance